COVAXIN is a highly purified and inactivated two dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with a safety track record of more than 300 million doses
Bharat Biotech has recruited of 13,000 volunteers, the half-way mark towards the goal of 26,000 participants for Phase 3 clinical trial of COVAXIN across multiple sites in India.
As per a statement from the company, the phase 3 human clinical trials of COVAXIN began mid-November after being evaluated in approximately 1000 subjects in Phase 1 and Phase 2 clinical trials, with promising safety and immunogenicity results, with acceptance in international peer reviewed scientific journals.
COVAXIN is being pegged as ‘India’s indigenous COVID-19 vaccine’, as it is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility.
COVAXIN is a highly purified and inactivated two dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with a safety track record of more than 300 million doses.
Thanking the volunteers signing up for the trial, Suchitra Ella, Joint Managing Director, Bharat Biotech said, “This pro-vaccine public health volunteerism is a morale booster for us to achieve our milestone target of 26,000 soon – Thank you volunteers Thank you India.”